Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Merida has developed a novel platform to precisely target the pathogenic antibodies that underpin a wide array of autoimmune and allergic diseases. The company is developing antib ...

IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Gómez-Sifontes, A. , Diaz-Tablero, J. and Rodriguez, Y. (2025) Anti-C1q Antibodies as Markers of Renal Involvement in Patients with Systemic Lupus Erythematosus, Bolivar City, Venezuela. Open Access ...

The drug is also in mid-stage clinical trials for primary membranous nephropathy (PMN) and antibody-mediated transplant rejection and is in phase 1 for lupus nephritis. According to the American ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). It still has a long way to go to reach that ...

Kidney disease is often called a “silent killer” because it progresses unnoticed until it reaches an advanced stage. Millions ...